Chiron Proleukin
Executive Summary
FDA grants orphan designation to recombinant interleukin-2 for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia. The company is designing a pivotal Phase III study for patients with HIV-associated NHL, and has begun a pediatric AML study. Proleukin is approved for treatment of metastatic renal cell carcinoma and metastatic melanoma